Marshall Wace, LLP Alnylam Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 268,932 shares of ALNY stock, worth $81.7 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
268,932
Previous 378,649
28.98%
Holding current value
$81.7 Million
Previous $89.1 Million
18.5%
% of portfolio
0.1%
Previous 0.11%
Shares
12 transactions
Others Institutions Holding ALNY
# of Institutions
721Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.09 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$3.97 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$2.9 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.17 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.34 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $37.4B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...